Loading clinical trials...
Loading clinical trials...
A Phase I, Open-label Clinical Pharmacology Study to Evaluate the Effect of Tipifarnib on Cardiac Safety in Subjects With Advanced Solid Malignancies
Conditions
Interventions
Tipifarnib
Locations
3
United States
Gabrail Cancer Center Research
Canton, Ohio, United States
NEXT Oncology
Austin, Texas, United States
NEXT Oncology
San Antonio, Texas, United States
Start Date
May 6, 2021
Primary Completion Date
May 2, 2023
Completion Date
May 2, 2023
Last Updated
September 21, 2023
NCT06898450
NCT05720117
NCT05719558
NCT05098132
NCT07477743
NCT06598800
Lead Sponsor
Kura Oncology, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions